SN-38
- Generic Name
- SN-38
- Brand Names
- Trodelvy
- Drug Type
- Small Molecule
- Chemical Formula
- C22H20N2O5
- CAS Number
- 86639-52-3
- Unique Ingredient Identifier
- 0H43101T0J
- Background
7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan Irinotecan, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negat...
- Indication
Investigated for use/treatment in colorectal cancer.
- Associated Conditions
- Hormone Receptor Positive Metastatic Breast Cancer, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Triple Negative Breast Cancers, Unresectable Triple-Negative Breast Carcinoma, Metastatic HR Positive, HER2/Neu Negative Breast Cancer, Unresectable Locally Advanced Triple-negative Breast Cancer, Unresectable, locally advanced HR Positive, HER2/Neu Negative Breast Cancer, Unresectable, locally advanced Hormone Receptor Positive Breast Carcinoma
- Associated Therapies
- -
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT04454437
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
- Conditions
- Interventions
- First Posted Date
- 2020-06-26
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Ana C Garrido-Castro, MD
- Target Recruit Count
- 110
- Registration Number
- NCT04448886
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT04434040
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸University of Chicago Medical Center for Advanced Care Orland Park, Orland Park, Illinois, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Yale University
- Target Recruit Count
- 50
- Registration Number
- NCT04251416
- Locations
- 🇺🇸
Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
Sacituzumab Govitecan In TNBC
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 260
- Registration Number
- NCT04230109
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital - North Shore Cancer Center, Danvers, Massachusetts, United States
Study of DF1001 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Dragonfly Therapeutics
- Target Recruit Count
- 378
- Registration Number
- NCT04143711
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT04039230
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2023-07-17
- Target Recruit Count
- 26
- Registration Number
- NCT03995706
- Locations
- 🇺🇸
Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
- Conditions
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT03992131
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Hope Rugo, MD
- Target Recruit Count
- 150
- Registration Number
- NCT03971409
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.